Answers are grounded in this paper and cite their sources.
This single-center retrospective cohort study compared sirolimus plus glucocorticoids with cyclosporine plus glucocorticoids in 37 and 35 patients with autoimmune hemolytic anemia/Evans syndrome, evaluating treatment response, long-term relapse, and exploratory patient-reported outcomes (PROs). Response and relapse were assessed longitudinally, and relapse-free survival was analyzed using time-to-event methods. PRO data (SF-36/HADS/FACIT) were available only for subsets of the sirolimus cohort and were not collected in the cyclosporine group. No statistically significant differences in overall or complete response rates were detected between the sirolimus (78.4% and 47.3%) and cyclosporine (80.0% and 52.8%) groups (P > 0.05). Median relapse-free survival was not reached in the sirolimus group versus 1455 days in the cyclosporine group (P < 0.05), and the overall relapse rate was lower (16.2% vs. 35.0%; P < 0.05). These findings are hypothesis-generating given the nonrandomized design, small heterogeneous cohort, baseline imbalances, and incomplete drug-level monitoring, and require confirmation in prospective studies.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: